Chest Journal Podcasts
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 140:56:39
- Mas informaciones
Informações:
Sinopsis
Each month, CHEST hosts a discussion with the authors of articles from the current issue, adding context and commentary to the challenges facing clinicians in the fields of pulmonary, critical care, and sleep medicine. As Podcast Editor and Moderator, D. Kyle Hogarth, MD, FCCP explains: "The goal of each conversation is to pique our listeners' interest and compel them to read additional work by the featured authors or on the topics covered."
Episodios
-
Reaction to the CMS Advisory Group Recommendation Not to Reimburse for Low-Dose CT Screening for Lung Cancer
16/05/2014 Duración: 46minThis month, CHEST Podcast Editor D. Kyle Hogarth, MD, FCCP, presents a special topic podcast on the recent vote of the Centers for Medicare and Medicaid Services (CMS) national coverage determination panel that there is not enough evidence to warrant Medicare coverage of low-dose CT screening for lung cancer. He is joined in conversation by Frank C. Detterbeck, MD, FCCP (Yale University), Scott Manaker, MD, PhD, FCCP (University of Pennyslvania), and David F. Yankelevitz, MD (Mount Sinai Hospital). They address some of the factors that went into the decision. Drs. Detterbeck, Manaker, and Yankelevitz also provide their interpretations of the important National Lung Screening Trial (NLST) and the results of studies from the International Early Lung Cancer Action Program (I-ELCAP), a multicenter clinical study in which patients were screened with CT using a common protocol.
-
Can the Interstitial Lung Disease-GAP Model Be Used to Accurately Predict Mortality in Chronic ILD Subtypes?
01/04/2014 Duración: 30minChristopher J. Ryerson, MD, and editorialist Athol U. Wells, MD, join CHEST Podcast Editor, D. Kyle Hogarth, MD, FCCP, to discuss the study by Dr. Ryerson and others extending the use of the GAP risk prediction model (which is based on gender, age, and lung physiology) for chronic interstitial lung disease (ILD) to patients with idiopathic pulmonary fibrosis (IPF) and non-IPF ILDs. They consider the utilty of applying a single clinical prediction model for accurate mortality estimation across multiple ILD subtypes and discuss the possibilities of staging.